[Application value of bone cement containing rhbFGF and RHBMP-2 in PKP treatment of osteoporotic lumbar compression fracture]

Zhongguo Gu Shang. 2024 Jan 25;37(1):15-20. doi: 10.12200/j.issn.1003-0034.20221048.
[Article in Chinese]

Abstract

Objective: To investigate the effect of bone cement containing recombinant human basic fibroblast growth factor (rhbFGF) and recombinant human bone morphogenetic protein-2 (rhBMP-2) in percutaneous kyphoplasty(PKP)treatment of osteoporotic vertebral compression fracture(OVCF).

Methods: A total of 103 OVCF patients who underwent PKP from January 2018 to January 2021 were retrospectively analyzed, including 40 males and 63 females, aged from 61 to 78 years old with an average of (65.72±3.29) years old. The injury mechanism included slipping 33 patients, falling 42 patients, and lifting injury 28 patients. The patients were divided into three groups according to the filling of bone cement. Calcium phosphate consisted of 34 patients, aged(65.1±3.3) years old, 14 males and 20 females, who were filled with calcium phosphate bone cement. rhBMP-2 consisted of 34 patients, aged (64.8±3.2) years old, 12 males and 22 females, who were filled with bone cement containing rhBMP-2. And rhbFGF+rhBMP-2 consisted of 35 patients, aged (65.1±3.6) years old, 14 males and 21 females, who were filled with bone cement containing rhbFGF and rhBMP-2. Oswestry disability index (ODI), bone mineral density, anterior edge loss height, anterior edge compression rate of injured vertebra, visual analog scale (VAS) of pain, and the incidence of refracture were compared between groups.

Results: All patients were followed for 12 months. Postoperative ODI and VAS score of the three groups decreased (P<0.001), while bone mineral density increased (P<0.001), anterior edge loss height, anterior edge compression rate of injured vertebra decreased first and then slowly increased (P<0.001). ODI and VAS of group calcium phosphate after 1 months, 6 months, 12 months were lower than that of rhBMP-2 and group rhbFGF+rhBMP-2(P<0.05), bone mineral density after 6 months, 12 months was higher than that of rhBMP-2 and group calcium phosphate(P<0.05), and anterior edge loss height, anterior edge compression rate of injured vertebra of group rhbFGF+rhBMP-2 after 6 months and 12 months were lower than that of group rhBMP-2 and group calcium phosphate(P<0.05). There was no statistical difference in the incidence of re-fracture among the three groups (P>0.05).

Conclusion: Bone cement containing rhbFGF and rhBMP-2 could more effectively increase bone mineral density in patients with OVCF, obtain satisfactory clinical and radiological effects after operation, and significantly improve clinical symptoms.

Keywords: Bone cement; Compression fracture; Lumbar spine; Osteoporosis; Percutaneous kyphoplasty; Recombinant human basic fibroblast growth factor; Recombinant human bone morphogenetic protein-2.

Publication types

  • English Abstract

MeSH terms

  • Aged
  • Bone Cements / therapeutic use
  • Bone Morphogenetic Protein 2*
  • Calcium Phosphates / therapeutic use
  • Female
  • Fibroblast Growth Factor 2*
  • Fractures, Compression* / complications
  • Fractures, Compression* / drug therapy
  • Fractures, Compression* / surgery
  • Humans
  • Kyphoplasty* / adverse effects
  • Male
  • Middle Aged
  • Osteoporotic Fractures* / drug therapy
  • Osteoporotic Fractures* / etiology
  • Osteoporotic Fractures* / surgery
  • Recombinant Proteins*
  • Retrospective Studies
  • Spinal Fractures* / complications
  • Spinal Fractures* / drug therapy
  • Spinal Fractures* / surgery
  • Transforming Growth Factor beta*
  • Treatment Outcome
  • Vertebroplasty* / adverse effects

Substances

  • Bone Cements
  • recombinant human bone morphogenetic protein-2
  • KCB-1 protein, recombinant
  • Calcium Phosphates
  • Recombinant Proteins
  • Transforming Growth Factor beta
  • Fibroblast Growth Factor 2
  • Bone Morphogenetic Protein 2